Relmada Therapeutics, Inc. (RLMD) Stock Score, Valuation & Financial Research

Relmada Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for RLMD

Relmada Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.24. These figures are a research snapshot, not a buy or sell recommendation.

What Relmada Therapeutics, Inc. does

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Relmada Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on the research and development of pharmaceutical candidates, requiring significant capital to fund clinical trials and regulatory processes, with future revenue dependent on successful commercialization and regulatory approval.

Products and services

  • The company is developing NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel for bladder cancer, and Sepranolone, a neurosteroid for Prader-Willi syndrome, Tourette syndrome, and essential tremor.

Customer types

Healthcare providers and patients (future potential).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party CROs and other vendors to conduct clinical trials and manage development activities; specific supplier names are unnamed. Source

Business relationships and partnerships

  • Asarina Pharma AB — Acquisition agreement for Sepranolone, involving potential milestone payments of up to approximately $200 million and a 3% royalty on net sales. Source

Business strengths to evaluate

  • Pipeline focused on high-value therapeutic areas with unmet medical needs Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing to continue operations Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

RLMD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.24
Market capitalization:
345.61M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -61.93M
Free cash flow:
USD -45.79M
Cash:
USD 11.33M
Total debt:
USD 0.00
EPS:
USD -0.92

What stands out

  • Free cash flow is USD -45.79M, negative for the stored period.
  • The balance sheet shows USD 11.33M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 11.33M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for RLMD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can RLMD fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is RLMD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for RLMD to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of RLMD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research RLMD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.